188 related articles for article (PubMed ID: 36414559)
21. [Lipid-lowering effect of drug pair Scutellariae Radix-Coptidis Rhizoma based on lipomics].
Liu WZ; Qian XJ; Zhang JQ; Liang K; Hu C; Wang XH
Zhongguo Zhong Yao Za Zhi; 2023 Dec; 48(24):6711-6720. PubMed ID: 38212031
[TBL] [Abstract][Full Text] [Related]
22. [Effects of Electroacupunctrue Combined with Dietary Control on Peroxisome Proliferator-activa- ted Receptor-α, and Liver Fatty Acid-binding Protein Levels in Non-alcoholic Fatty Liver Disease Rats].
Zhang Y; Tang CL; Tian Y; Yuan HZ; Yang H; Tang NZ; Gao RQ; Cao J
Zhen Ci Yan Jiu; 2015 Oct; 40(5):345-51. PubMed ID: 26669188
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic role of Artemether in the prevention of hepatic steatosis through miR-34a-5p/PPARα pathway.
Chen L; Yu S; Hong S; Lin X; Zhu X; Cao X; Li Y; Xiao H
Drug Dev Res; 2023 Apr; 84(2):156-171. PubMed ID: 36541217
[TBL] [Abstract][Full Text] [Related]
24. Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.
Li R; Zhu W; Huang P; Ding C; Tang Y; Lian P; Huang X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):730-738. PubMed ID: 35837772
[TBL] [Abstract][Full Text] [Related]
25. Jianpi Shengqing Huazhuo Formula improves abnormal glucose and lipid metabolism in obesity by regulating mitochondrial biogenesis.
Wang W; Chen S; Xu S; Liao G; Li W; Yang X; Li T; Zhang H; Huang H; Zhou Y; Pan H; Lin C
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117102. PubMed ID: 37660955
[TBL] [Abstract][Full Text] [Related]
26. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
27. Schisandra chinensis prevents alcohol-induced fatty liver disease in rats.
Park HJ; Lee SJ; Song Y; Jang SH; Ko YG; Kang SN; Chung BY; Kim HD; Kim GS; Cho JH
J Med Food; 2014 Jan; 17(1):103-10. PubMed ID: 24456360
[TBL] [Abstract][Full Text] [Related]
28. [Difference of lipid-lowering efficacy of "Xinjianqu" before and after fermentation and its mechanism based on LKB1-AMPK pathway and 16S rDNA sequencing technology].
Li DH; Wang RS; Zhang ZL; Zhu JG; Sun MM; Qiao J
Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(8):2146-2159. PubMed ID: 37282903
[TBL] [Abstract][Full Text] [Related]
29. [Effect of Fuzi Lizhong decoction in reducing liver injury of rats with non-alcoholic fatty liver via activating AMPK and suppressing NF-κBp65 pathway].
Yang JY; Shi ZH; Ma W; Tao DQ; Liu S; Chen L; Zhou XL
Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3176-3183. PubMed ID: 30200715
[TBL] [Abstract][Full Text] [Related]
30. Dietary supplementation of salidroside alleviates liver lipid metabolism disorder and inflammatory response to promote hepatocyte regeneration via PI3K/AKT/Gsk3-β pathway.
Cui Z; Jin N; Amevor FK; Shu G; Du X; Kang X; Ning Z; Deng X; Tian Y; Zhu Q; Wang Y; Li D; Zhang Y; Wang X; Han X; Feng J; Zhao X
Poult Sci; 2022 Sep; 101(9):102034. PubMed ID: 35926351
[TBL] [Abstract][Full Text] [Related]
31. Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism.
Karimi-Sales E; Ebrahimi-Kalan A; Alipour MR
Biomed Pharmacother; 2019 Jan; 109():1306-1312. PubMed ID: 30551380
[TBL] [Abstract][Full Text] [Related]
32. Establishment of an alcoholic fatty liver disease model in mice.
Tan P; Liang H; Nie J; Diao Y; He Q; Hou B; Zhao T; Huang H; Li Y; Gao X; Zhou L; Liu Y
Am J Drug Alcohol Abuse; 2017 Jan; 43(1):61-68. PubMed ID: 27739874
[TBL] [Abstract][Full Text] [Related]
33. Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression.
Zhang N; Qu Y; Qin B
Clin Exp Pharmacol Physiol; 2021 Aug; 48(8):1125-1136. PubMed ID: 33721354
[TBL] [Abstract][Full Text] [Related]
34. [Berberine alleviates programmed necrosis of metabolic-associated fatty liver disease via activating Nrf2 pathway in mice].
Hao MY; Sun LL; Sheng MW; Lyu YS; Lin YB; Yang YH; Zhi JH; Yu WL; Du HY
Zhonghua Gan Zang Bing Za Zhi; 2022 Feb; 30(2):224-229. PubMed ID: 35359076
[No Abstract] [Full Text] [Related]
35. [Effect of apigenin on protein expressions of PPARs in liver tissues of rats with nonalcoholic steatohepatitis].
Shi T; Zhuang R; Zhou H; Wang F; Shao Y; Cai Z
Zhonghua Gan Zang Bing Za Zhi; 2015 Feb; 23(2):124-9. PubMed ID: 25880979
[TBL] [Abstract][Full Text] [Related]
36. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease.
Ding J; Li M; Wan X; Jin X; Chen S; Yu C; Li Y
Sci Rep; 2015 Sep; 5():13729. PubMed ID: 26330104
[TBL] [Abstract][Full Text] [Related]
37. Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat.
Jiang W; Guo MH; Hai X
World J Gastroenterol; 2016 Dec; 22(46):10180-10188. PubMed ID: 28028366
[TBL] [Abstract][Full Text] [Related]
38. [Mechanism of catgut embedding at back-
Zhou XL; Tang N; Wu T; Zhang Y; Chen Q; Wei WH; Zhou YN; Zhang DX; Qin FC; Yang W
Zhongguo Zhen Jiu; 2020 Jan; 40(1):59-66. PubMed ID: 31930901
[TBL] [Abstract][Full Text] [Related]
39. circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling.
Guo XY; Sun F; Chen JN; Wang YQ; Pan Q; Fan JG
World J Gastroenterol; 2018 Jan; 24(3):323-337. PubMed ID: 29391755
[TBL] [Abstract][Full Text] [Related]
40. Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice.
Kang K; Sun Y; Pan D; Sang LX; Sun MJ; Li YL; Chang B
Exp Ther Med; 2021 May; 21(5):418. PubMed ID: 33777186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
